Review Article

Tetrahydrobiopterin Improves Endothelial Function in Cardiovascular Disease: A Systematic Review

Qiongying Wang, Mina Yang, Han Xu, and Jing Yu

Department of Cardiology, The Second Hospital of Lanzhou University, 82 Cuiyingmen Street, Lanzhou, Gansu 730030, China

Correspondence should be addressed to Jing Yu; yujing2304@126.com

Received 13 October 2014; Accepted 20 November 2014; Published 4 December 2014

Academic Editor: Yoshiji Ohta

Copyright © 2014 Qiongying et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Tetrahydrobiopterin (BH$_4$) is a cofactor of nitric oxide synthase (NOS). Nitric oxide (NO) bioavailability is reduced during the early stage of vascular diseases, such as coronary artery disease, hypercholesterolemia, hypertension, and diabetic vasculopathy, and even throughout the entire progression of atherosclerosis.

Methods. A literature search was performed using electronic databases (up to January 31, 2014), including MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), using an established strategy.

Results. Fourteen articles were selected with a total of 370 patients. Ten of the fourteen studies showed a significant improvement in the endothelial dysfunction of various cardiovascular disease groups with BH$_4$ supplementation compared with the control groups or placebos. Three studies showed no positive outcome, and one study showed that low-dose BH$_4$ had no effect but that high-dose BH$_4$ did have a significantly different result.

Conclusions. This review concludes that supplementation with BH$_4$ and/or augmentation of the endogenous levels of BH$_4$ will be a novel approach to improve the endothelial dysfunction observed in various cardiovascular diseases. BH$_4$ might be considered to be a new therapeutic agent to prevent the initiation and progression of cardiovascular disease.

1. Introduction

Cardiovascular diseases (CVDs), such as coronary artery disease, hypercholesterolemia, diabetes, hypertension, and stroke, remain the largest cause of mortality and morbidity in the world. In 2014, the attributable fractions of adjusted estimated population for the mortality of CVDs are as follows: 40.6% for high blood pressure, 13.7% for smoking, 13.2% for poor diet, 11.9% for insufficient physical activity, and 8.8% for abnormal blood glucose levels [1]. Abnormal endothelial function appeared as an early feature of all CVDs and risk factor syndromes, resulting in the loss of normal homeostatic pathways that act to inhibit disease processes such as inflammation, thrombosis, and oxidative stress [2, 3].

The endothelium is the largest endocrine organ in the human body and can be involved in the control of vascular tone, platelet reactivity, coagulation, and permeability [4]. Thus, healthy endothelium can protect against excessive/abnormal inflammation and coagulation [5], which are the key processes in CVD development and progression. Furthermore, endothelial function was demonstrated to serve as a predictor of cardiovascular events [6, 7]. Therefore, the evaluation of endothelial function is vital to generate and determine a more effective or final therapeutic strategy for cardiovascular diseases. From a pathophysiologic standpoint, there is an important focus on the prevention and treatment of vascular diseases via the restoration of the normal biosynthesis of nitric oxide (NO) and the reduction of the excessive generation of superoxide anions and reactive oxygen species (ROS).

Tetrahydrobiopterin (BH$_4$) is an essential cofactor for a set of enzymes that are of pivotal metabolic importance, including four aromatic amino acid hydroxylases (AAAH), three nitric oxide synthases (NOS), and alkylglycerol monooxygenase (AGMO). Phenylalanine hydroxylase (PAH) was the first enzyme recognized to depend on BH$_4$ [8]. Phenylketonuria is a genetic disorder characterized by a deficiency of PAH; BH$_4$ may provide good phenylalanine control in the patients who respond to oral administration of BH$_4$. NOS is a critical enzyme militated in the production of the messenger molecule NO, which is generated from L-arginine. BH$_4$ is inseparably considered to be a cofactor of NOS enzymes for the progression of NO synthesis [9, 10].
When BH₄ is limited, under the conditions of oxidative stress, BH₄ can be readily oxidized to dihydrobiopterin (BH₂) and eventually converted into biopterin, especially when NOS cofactor activity is not needed. When NOS is uncoupled, ROS rather than NO is produced. NO is used as a soluble gas continuously synthesized from the amino acid L-arginine in endothelial cells via the constitutive calcium-calmodulin-dependent enzyme NOS. This substance has a wide variety of biological properties that maintain vascular homeostasis, including the modulation of vascular dilator tone, regulation of local cell growth, and protection of the vessel from the injurious consequences of platelets and cells circulating in the blood. In the early period of different CVDs, the bioavailability of NO is reduced. In humans, endothelial function is altered in different subjects with vascular disease status and correlated with risk factor profiles [2, 11]. Importantly, several prospective studies have identified that supplementation with BH₄ improves endothelial function in patients with coronary artery disease, hypercholesterolemia, hypertension, and diabetic vasculopathy [12–15]. Moreover, there are published clinical studies of BH₄ therapy in the pathogenesis of other vascular diseases, such as pulmonary hypertension [16] and smoking [17, 18], as well as in aging [19–21].

In this regard, supplementation with BH₄ and/or strategies that augment the endogenous levels of BH₄ have been recently identified to be novel approaches that can exert salutary effects on the endothelial dysfunction induced by a variety of vascular diseases. This concept and its therapeutic implications are the focus of considerable investigation, which will likely generate an enlarged spectrum of therapeutic agents available for CVDs.

2. Materials and Methods

A systematic review of the literature concerning BH₄ to improve vascular endothelial function in adult patients was conducted using the recommended guidelines provided by the Cochrane Handbook for the Systematic Reviews of Interventions.

2.1. Search Methods for the Identification of Studies. To select eligible studies, a search was performed of electronic databases, including PUBMED, MEDLINE, and the Cochrane Library, using a search strategy that depended on combinations of the keywords tetrahydrobiopterin/BH₄ and endothelial function or endothelial dysfunction. The last search was updated to January 31, 2014. We deliberately broadened the search to ensure the inclusion of all relevant articles. All the bibliographies of papers retrieved from the search were also screened for additional articles. Only full publications in peer-reviewed journals were selected for potential inclusion in the review.

2.2. Study Selection Criteria. Two reviewers independently assessed titles, abstracts, and/or the full-text papers of the records retrieved from the electronic database searches for possible inclusion according to the predefined selection criteria: (1) type of study, only RCTs were selected for further assessment; (2) participants, only CVD patients older than 18 years were included, regardless of gender; (3) type of intervention, the intervention used any generation of BH₄, alone or combined with other substances, irrespective of the administration approach, and the intervention in the control group was a placebo, alone or combined with other substances; and (4) outcomes, trials focused on the effect of supplementation of BH₄ on endothelial function in patients with CVD.

2.3. Quality Assessment. This study is a “qualitative systematic review” without a meta-analysis. The methodological quality of the RCTs was assessed independently by two reviewers (see Table 1) according to the methods recommended in Section Six of the Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0.

3. Results

3.1. Description of Selected Studies. Citations and abstracts were downloaded into Mendeley and Endnote 6 by independent researchers, and any duplicates were deleted. The main search strategy identified 802 publications, and 356 were excluded because of duplication (Figure 1).

A preliminary screening of the titles and abstracts was performed according to the following inclusion criteria: studies related to BH₄ and endothelial function. We excluded reviews, meeting notes, book chapters, animal experiments employing qualitative methods, findings derived from qualitative methods, interviews, and observations or participant observations. Access to the full text of the remaining articles was then sought (see Figure 1).

3.2. Tetrahydrobiopterin in the Treatment of Cardiovascular Disease. In a range of in vivo pharmacological experiments,
clinical studies have been employed to explore the role of BH4 on eNOS function in the context of cardiovascular diseases, including coronary artery disease, hypercholesterolemia, hypertension, and diabetic vasculopathy. Based on the resulting experimental evidence, endothelial BH4 bioavailability has emerged as a rational therapeutic target in vascular disease states (see Table 2).

### 3.3. Coronary Artery Disease

BH4 was administered acutely or on a short-term basis, delivered via intracoronary/intra-arterial infusion [13, 22–25]. In one study, oral BH4 was used at a low dose (400 mg/d) or high dose (700 mg/d) for 2 to 6 weeks [26]. In another study, BH4 alone did not influence the vessel area but did prevent vasoconstriction in response to acetylcholine (ACh) (+2 ± 3%, NS, versus baseline) in 15 of the patients with endothelial dysfunction in the trial. Correspondingly, calculated volume flow showed the highest value after coinfusion with Ach and BH4 [25]. BH4 significantly improved acetylcholine-induced increases in coronary blood flow (CBF) in patients with diminished flow responses but exerted no effect in those with normal flow responses [22]. However, no difference was observed in the Ach response due to the coinfusion of BH4 and Ach with respect to the % change in CBF [24]. Settergren et al. found that the endothelium-dependent vasodilation was significantly less reduced at 15 and 30 min of reperfusion following L-arginine and BH4 infusion than with saline infusion [25]. BH4 did not affect the relative changes in the brachial artery diameter from baseline flow-mediated vasodilatation (FMD) (%) in type 2 diabetic and coronary heart disease patients [23]. Oral BH4 treatment for 2 to 6 weeks significantly augmented the BH4 levels in plasma but had no effect on the vascular redox state or endothelial function [26].

### 3.4. Hypercholesterolemia

The method of administration was mainly infusion via the brachial artery [27–29] or coronary ostium [30]. 22 hypercholesterolemic patients were randomized into groups receiving 4 weeks of oral BH4 (400 mg twice daily) or placebo [14]. In all studies, BH4 restored the vascular function in the patients with hypercholesterolemia. BH4 also restored the endothelial function of coronary arteries in the patients with hypercholesterolemia [28, 30]. BH4 attenuated the Ach-induced decrease in coronary diameter and restored the Ach-induced increase in coronary blood flow [30]. BH4 increased exercise-induced hyperemia in all subjects but had no influence on myocardial blood flow (MBF) at rest or during adenosine-induced hyperemia in all subjects. Flow reserve utilization was increased significantly in hypercholesterolemic subjects but remained unchanged in controls [28]. The vasoconstrictor response to L-monomethyl-arginine (L-NMMA) was significantly increased with BH4 treatment compared with saline infusion ($P < 0.05$); additionally, the impaired

---

**Table I: Basic characteristics of the included clinical trials.**

| Study, year       | Methods                                      | BH4-treated | Placebo |
|-------------------|----------------------------------------------|-------------|---------|
| Maier et al., 2000 [13] | Randomized                                 | 19 3/16 56 ± 10 | * * * |
| Setoguchi et al., 2001 [22] | Randomized                                 | 15 10/5 60 ± 11 | * * * |
| Nyström et al., 2004 [23] | Randomized; single-blind crossover          | 5 5/0 57 ± 2  | 5 5/0 57 ± 2 |
| Worthley et al., 2007 [24] | Randomized controlled                       | 22 4/18 60 ± 9 | 5 * |
| Settergren et al., 2009 [25] | Randomized; blind, crossover                | 12 12/0 71 ± 1,5 | * |
| Cunnington et al., 2012 [26] | Randomized; double-blind; parallel design   | 30 3/27 * | 19 3/16 68 ± 2 |
| Stroes et al., 1997 [27] | Randomized controlled                       | 13 9/4 32 ± 4 | * |
| Fukuda et al., 2002 [30] | Randomized controlled                       | 9 7/2 61 ± 9 | * |
| Wyss et al., 2005 [28] | Randomized controlled                       | 9 7/2 59 ± 9 | * |
| Holowatz and Kenney, 2011 [29] | Randomized controlled                     | 9 6/3 53 ± 3 | * |
| Cosentino et al., 2008 [14] | Randomized; double-blind; parallel design  | 11 7/4 61 ± 9 | 10 10/0 54 ± 10 |
| Higashi et al., 2002 [31] | Randomized controlled                       | 8 6/2 48 ± 11 | * |
| Porkert et al., 2008 [12] | Randomized                                 | 8 6/2 44 ± 9 | * |
| Heitzer et al., 2000 [15] | Randomized controlled                       | 24 9/15 * | * |
| Cunningham et al., 2012 [26] | Randomized; double-blind; parallel design  | 23 7/16 52 ± 2 | * |
| Worthley et al., 2007 [24] | Randomized controlled                       | 22 4/18 60 ± 9 | 5 * |
| Setoguchi et al., 2001 [22] | Randomized                                 | 15 10/5 60 ± 11 | * * * |
| Nyström et al., 2004 [23] | Randomized; single-blind crossover          | 5 5/0 57 ± 2  | 5 5/0 57 ± 2 |
| Worthley et al., 2007 [24] | Randomized controlled                       | 22 4/18 60 ± 9 | 5 * |
| Settergren et al., 2009 [25] | Randomized; blind, crossover                | 12 12/0 71 ± 1,5 | * |
| Cunnington et al., 2012 [26] | Randomized; double-blind; parallel design   | 30 3/27 * | 19 3/16 68 ± 2 |
| Stroes et al., 1997 [27] | Randomized controlled                       | 13 9/4 32 ± 4 | * |
| Fukuda et al., 2002 [30] | Randomized controlled                       | 9 7/2 61 ± 9 | * |
| Wyss et al., 2005 [28] | Randomized controlled                       | 9 7/2 59 ± 9 | * |
| Holowatz and Kenney, 2011 [29] | Randomized controlled                     | 9 6/3 53 ± 3 | * |
| Cosentino et al., 2008 [14] | Randomized; double-blind; parallel design  | 11 7/4 61 ± 9 | 10 10/0 54 ± 10 |
| Higashi et al., 2002 [31] | Randomized controlled                       | 8 6/2 48 ± 11 | * |
| Porkert et al., 2008 [12] | Randomized                                 | 8 6/2 44 ± 9 | * |
| Heitzer et al., 2000 [15] | Randomized controlled                       | 24 9/15 * | * |
null
augments forearm vessel endothelium-dependent vasodilation by improving endothelial dysfunction [25, 27, 31]. The flow reserve utilization of the coronary microcirculation in hypercholesterolemic subjects is significantly reduced but is nearly restored after BH₄ infusion [28]. BH₄ augmented NO-dependent vasodilatation during local heating by increasing the plateau in skin blood flow in hypercholesterolemic humans [29].

These studies involved a limited number of patients in whom BH₄ was administered acutely or on a short-term basis, and BH₄ was typically delivered via intracoronary/intracranial infusion, which is not representative of a suitable route of administration for chronic disease management. The breadth of preclinical and acute clinical data implicating BH₄ as a key regulator in endothelial function suggests that oral BH₄ therapy may be able to prevent or treat CVDs. Clinical trials investigating oral BH₄ supplementation have shown varied efficacy in numerous disorders with an apparent lack of efficacy in diseases such as hypertension, hypercholesterolemia, and coronary artery disease. Porekt and coworkers showed that oral BH₄ at a daily dose of 400 mg or higher has a significant and sustained antihypertensive effect in subjects with poorly controlled hypertension but that lower dose (200 mg per day) BH₄ has no effect [12]. Twenty-two hypercholesterolemic patients were randomized to receive 4 weeks of either oral BH₄ (400 mg twice daily) or placebo, and age-matched healthy volunteers served as controls. They found that chronic BH₄ treatment led to an eightfold increase in plasma BH₄ levels and restored the impairment in endothelium-dependent relaxation due to Ach in hypercholesterolemic patients but did not affect control subjects. Importantly, they also demonstrated that BH₄ significantly reduced the plasma levels of 8-F2 isoprostane, a marker of oxidative stress, and that the effect of BH₄ treatment on NO bioavailability is independent of any change in LDL cholesterol [14]. In contrast, oral low-dose (400 mg/d) or high-dose (700 mg/d) BH₄ for 2 to 6 weeks in patients with established coronary artery disease significantly elevated plasma BH₄ levels. However, this elevation in plasma BH₄ was tempered by similar rises in plasma BH₃ and biopterin, so that the ratio of reduced bipterins to oxidized ones (BH₃/ [BH₂+biopterin]) in plasma remained unchanged after treatment, with neither molecule having an effect on the vascular redox state or endothelial function [26]. In addition, a phase 2 clinical trial sponsored by the US pharmaceutical company BioMarin failed to observe an ameliorative effect of the oral administration of BH₄ in patients with poorly controlled hypertension. There are studies providing preliminary evidence that oral BH₄ could increase artery compliance and decrease arterial stiffness in healthy older men [33] or estrogen-deficient postmenopausal women [34]. 6R-BH₄ was administered starting at a dose of 2.5 mg/kg and increasing to 20 mg/kg over 8 weeks. This treatment produced an improvement in the 6-minute walking distance, with the most significant improvement at a dose of 5 mg/kg, in patients with pulmonary hypertension [16].

The vascular effects following the oral administration of BH₄ appear complex and dose dependent, which may be explained by either the rapid clearance of BH₄ after oral administration and/or an enhanced oxidation to BH₂, which lacks eNOS cofactor activity. Thus, systemic oxidative stress may play a critical role in determining the degree of oxidation of BH₄ to BH₂ and hence the ratio of BH₄ : BH₂ and efficacy of the treatment [26]. Recent data from cultured endothelial cells [35, 36] suggest that the intracellular levels of BH₃ and, more specifically, the ratio between reduced and oxidized bipterins are important in regulating eNOS coupling. Considering that BH₄ is easily oxidized to BH₂, strategies should increase the supplementation of BH₄ with antioxidants. On one hand, they can reduce the oxidation of BH₄ to BH₂; on the other hand, they may synergistically decrease oxidative stress and increase nitric oxide. This hypothesis is supported by observations in which the antioxidant vitamin C stimulates eNOS enzymatic activity by increasing the intracellular concentration of BH₄ [33, 37]. Vitamin C likely exerted its beneficial effects in that study through a variety of molecular mechanisms. In its capacity as an antioxidant, it enhances NO bioavailability by quenching O₂−, thus limiting the inactivation of NO that occurs when O₂− and NO combine to produce OONO− [38]. Vitamin C also stabilizes existing BH₄ [39] and increases endothelial BH₄ synthesis [40]. We have demonstrated that plasma bipterin oxidation status is closely linked to the amount of ascorbate in plasma and hence in the diet in vivo [41]. However, studies in larger cohorts of patients would be required to determine whether this dual (BH₄ plus antioxidant) intervention would be efficacious on a chronic basis.

In addition, acute or short-term supplementation with BH₄ via intracoronary/intracranial infusion has no beneficial effect on endothelial dysfunction in CVDs [23, 24]. These findings suggest that, in humans, BH₄ does not passively diffuse from the circulating blood into the vascular endothelium. Previous work has indicated that bipterin transport is cell type dependent and that both direct uptake (as BH₃) and conversion to BH₂ followed by recycling via dihydrofolate reductase (DFHR) are possible mechanisms [42]. In fact, in patients with coronary artery atherosclerosis, high plasma levels of BH₄ are associated with low BH₄ levels in the endothelium [43]. To ensure that BH₄ is imported into the endothelium, it must undergo oxidation to BH₂; imported BH₂ is then regenerated back to BH₄ by DHFR. A recent study found that human DHFR has very low affinity for 7,8-BH₂, which lacks eNOS cofactor activity. More studies should be directed toward interventions that can favorably alter the endogenous BH₄/BH₂ ratio in the human vascular endothelium via a

5. Conclusion
In summary, targeting BH₄ remains a rational therapeutic strategy in CADs. However, we found that oral BH₄ treatment in patients with CADs significantly elevates the BH₄ levels in blood but that this effect is significantly limited by the systemic oxidation of exogenous BH₄ to BH₂, which lacks eNOS cofactor activity. More studies should be directed toward interventions that can favorably alter the endogenous BH₄/BH₂ ratio in the human vascular endothelium via a
selective increase in the absolute BH$_4$ levels, the prevention of BH$_4$ oxidation, or an increase in BH$_4$ recycling. In particular, the effect of antioxidant coadministration to prevent the systemic and vascular oxidation of exogenous BH$_4$ warrants further attention. Beneficial effects of acute BH$_4$ supplementation on endothelial function have been reported in many human studies. However, the long-term based clinical trials are deficient. Oral administration can be considered to be representative of a suitable administration route for chronic disease management. Therefore, long-term experiments investigating oral BH$_4$ supplementation are needed.

**Conflict of Interests**

The authors declare that there is no conflict of interests.

**Authors’ Contribution**

Qiongying Wang and Mina Yang contributed equally to this work.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (NSFC 81270332), Gansu Province Natural Science Foundation (110FKCA150), Gansu Administration of Traditional Medicine Foundation (GZK-2010-Z-1), and Foundation of the Second Hospital of Lanzhou University (YJ2010-02 and YJzy2013-05).

**References**

[1] A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics–2013 update: a report from the american heart association,” *Circulation*, vol. 127, no. 1, pp. e6–e245, 2013.

[2] H. Cai and D. G. Harrison, “Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress,” *Circulation Research*, vol. 87, no. 10, pp. 840–844, 2000.

[3] T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, and T. Münzel, “Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease,” *Circulation*, vol. 104, no. 22, pp. 2673–2678, 2001.

[4] A. A. Quyyumi, “Prognostic value of endothelial function,” *The American Journal of Cardiology*, vol. 91, no. 12, pp. 19–24, 2003.

[5] B. Healy, “Endothelial cell dysfunction: an emerging endocrinopathy linked to coronary disease,” *Journal of the American College of Cardiology*, vol. 16, no. 2, pp. 357–358, 1990.

[6] J. P. J. Halcox, W. H. Schenke, G. Zalos et al., “Prognostic value of coronary vascular endothelial dysfunction,” *Circulation*, vol. 106, no. 6, pp. 653–658, 2002.

[7] R. Fathi, B. Halaska, N. Isbel, L. Short, and T. H. Marwick, “The relative importance of vascular structure and function in predicting cardiovascular events,” *Journal of the American College of Cardiology*, vol. 43, no. 4, pp. 616–623, 2004.

[8] E. R. Werner, N. Blau, and B. Thöny, “Tetrahydrobiopterin: biochemistry and pathophysiology,” *Biochemical Journal*, vol. 438, no. 3, pp. 397–414, 2011.

[9] M. A. Tayeh and M. A. Marletta, “Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor,” *Journal of Biological Chemistry*, vol. 264, no. 33, pp. 19654–19658, 1989.

[10] N. S. Kwon, C. F. Nathan, and D. J. Stuehr, “Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages,” *The Journal of Biological Chemistry*, vol. 264, no. 34, pp. 20496–20501, 1989.

[11] J. M. Hill, G. Zalos, J. P. J. Halcox et al., “Circulating endothelial progenitor cells, vascular function, and cardiovascular risk,” *The New England Journal of Medicine*, vol. 348, no. 7, pp. 593–600, 2003.

[12] M. Porkert, S. Sher, U. Reddy et al., “Tetrahydrobiopterin: a novel antihypertensive therapy,” *Journal of Human Hypertension*, vol. 22, no. 6, pp. 401–407, 2008.

[13] W. Maier, F. Cosentino, R. B. Lütolf et al., “Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease,” *Journal of Cardiovascular Pharmacology*, vol. 35, no. 2, pp. 173–178, 2000.

[14] F. Cosentino, D. Hürlimann, C. Delli Gatti et al., “Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia,” *Heart*, vol. 94, no. 4, pp. 487–492, 2008.

[15] T. Heitzer, K. Krohn, S. Albers, and T. Meinertz, “Tetrahydrobiopterin improves endothelium-dependent vasodilation in patients with Type II diabetes mellitus,” *Diabetologia*, vol. 43, no. 11, pp. 1435–1438, 2000.

[16] I. M. Robbins, A. R. Hemmes, J. S. Gibbs et al., Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension,” *Experimental Lung Research*, vol. 37, no. 1, pp. 26–34, 2011.

[17] T. Heitzer, C. Brockhoff, B. Mayer et al., “Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase,” *Circulation Research*, vol. 86, no. 2, pp. e36–e41, 2000.

[18] S. Ueda, H. Matsuoka, H. Miyazaki, M. Usui, S. Okuda, and T. Imaizumi, “Tetrahydrobiopterin restores endothelial function in long-term smokers,” *Journal of the American College of Cardiology*, vol. 35, no. 1, pp. 71–75, 2000.

[19] J. A. Lang, L. A. Holowatz, and W. L. Kenney, “Localized tyrosine or tetrahydrobiopterin supplementation corrects the age-related decline in cutaneous vasoconstriction,” *The Journal of Physiology*, vol. 588, no. 8, pp. 1361–1368, 2010.

[20] A. E. Staniewicz, R. S. Bruning, C. J. Smith, W. L. Kenney, and L. A. Holowatz, “Local tetrahydrobiopterin administration augments reflex cutaneous vasodilation through nitric oxide-dependent mechanisms in aged human skin,” *Journal of Applied Physiology*, vol. 112, no. 5, pp. 791–797, 2012.

[21] G. L. Pierce, K. L. Jablonski, A. E. Walker et al., “Tetrahydrobiopterin supplementation enhances carotid artery compliance in healthy older men: a pilot study,” *American Journal of Hypertension*, vol. 25, no. 10, pp. 1050–1054, 2012.

[22] S. Setoguchi, M. Mohri, H. Shimokawa, and A. Takeshita, “Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease,” *Journal of the American College of Cardiology*, vol. 38, no. 2, pp. 493–498, 2001.

[23] T. Nyström, A. Nygren, and Å. Sjöholm, “Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease,” *The American Journal of Physiology*, vol. 287, no. 5, pp. E919–E925, 2004.
human coronary arteries,” Cardiovascular Research, vol. 76, no. 3, pp. 539–546, 2007.

[25] M. Settgren, F. Böhm, R. E. Malmström, K. M. Channon, and J. Pernow, “L-Arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease,” Atherosclerosis, vol. 204, no. 1, pp. 73–78, 2009.

[26] C. Cunnington, T. Van Assche, C. Shirodaria et al., “Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease,” Circulation, vol. 125, no. 11, pp. 1356–1366, 2012.

[27] E. Stroes, J. Kastelein, J. Kastelein, F. Cosentino et al., “Tetrahydrobiopterin levels and nitric oxide synthase activity,” The Journal of Clinical Investigation, vol. 99, no. 1, pp. 41–46, 1997.

[28] C. A. Wyss, P. Kneipfli, N. Namdar et al., “Tetrahydrobiopterin restores endothelial function in hypercholesterolaemia,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 1, pp. 84–91, 2005.

[29] L. A. Holowatz and W. L. Kenney, “Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans,” The Journal of Physiology, vol. 589, no. 19, pp. 4787–4797, 2011.

[30] Y. Fukuda, H. Teragawa, K. Matsuda, T. Yamagata, H. Matsuura, and K. Chayama, “Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia,” Heart, vol. 87, no. 3, pp. 264–269, 2002.

[31] Y. Higashi, S. Sasaki, K. Nakagawa et al., “Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals,” The American Journal of Hypertension, vol. 15, no. 4, pp. 326–332, 2002.

[32] N. Ihlemann, C. Rask-Madsen, A. Perner et al., “Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 285, no. 2, pp. H875–H882, 2003.

[33] J. Yan, G. Tie, and L. M. Messina, “Tetrahydrobiopterin, L-arginine and vitamin C act synergistically to decrease oxidant stress and increase nitric oxide that increases blood flow recovery after hindlimb ischemia in the rat,” Molecular Medicine, vol. 18, no. 8, pp. 1221–1230, 2012.

[34] K. L. Moreau, A. Meditz, K. D. Deane, and W. M. Kohrt, “Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 302, no. 5, pp. H1211–H1218, 2012.

[35] M. J. Crabtree, C. L. Smith, G. Lam, M. G. Goligorsky, and S. S. Gross, “Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicted changes in NO vs. superoxide production by eNOS,” Molecular Genetics and Metabolism, vol. 92, no. 1, pp. 47–57, 2007.

[36] M. J. Crabtree, C. L. Smith, G. Lam, M. G. Goligorsky, and S. S. Gross, “Control of endothelial nitric oxide synthase by tetrahydrobiopterin,” Circulation Research, vol. 100, no. 1, pp. 117–127, 2007.

[37] L. V. d’Uscio, S. Milstien, D. Richardson, L. Smith, and Z. S. Katsuc, “Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity,” Circulation Research, vol. 92, no. 1, pp. 88–95, 2003.

[38] P. Pacher, J. S. Beckman, and L. Liaudet, “Nitric oxide and peroxynitrite in health and disease,” Physiological Reviews, vol. 87, no. 1, pp. 315–424, 2007.

[39] R. T. Heller, G. Behaun, B. Schellenberg, B. Mayer, G. Wernerv-Felmeyer, and E. R. Werner, “L-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin,” The Journal of Biological Chemistry, vol. 276, no. 1, pp. 40–47, 2001.

[40] A. Huang, J. V. Vita, R. C. Venema, and J. F. Keaney Jr., “Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin,” The Journal of Biological Chemistry, vol. 275, no. 23, pp. 17399–17406, 2000.

[41] A. Mortensen, S. Hasselholt, P. Thyde-Nyborg, and J. Lykkefeldt, “Guinea pig ascorbate status predicts tetrahydrobiopterin plasma concentration and oxidation ratio in vivo,” Nutrition Research, vol. 33, no. 10, pp. 859–867, 2013.

[42] K. Sawabe, Y. Suetake, N. Nakanishi, K. O. Wakasugi, J. Hasegawa, “Cellular accumulation of tetrahydrobiopterin following its administration is mediated by two different processes; direct uptake and indirect uptake mediated by a methotrexate-sensitive process,” Molecular Genetics and Metabolism, vol. 86, pp. 133–138, 2005.

[43] C. Antoniades, C. Shirodaria, M. Crabtree et al., “Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation,” Circulation, vol. 116, no. 24, pp. 2851–2859, 2007.

[44] J. Whitsett, A. R. Filho, S. Sethumadhavan, J. Celinska, M. Wlidskaj, and J. Vasquez-Vivar, “Human endothelial dihydrofolate reductase low activity limits vascular tetrahydrobiopterin recycling,” Free Radical Biology and Medicine, vol. 63, pp. 143–150, 2013.